CA
RNAC icon

Clearstead Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Clearstead Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94 Buy
+9
New +$67 ﹤0.01% 3373

Other funds holding RNAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FA
Fedenia Advisers Madison, Wisconsin $421M AUM 96.46% 1-Year Est. Return
TFCP
Twin Focus Capital Partners Boston, Massachusetts $983M AUM 37.07% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Clearstead Advisors's RNAC Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 9 shares worth $94. The stake represents ﹤0.01% of the portfolio and ranks #3373 among its holdings.

31 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Clearstead Advisors held 9 shares of Cartesian Therapeutics worth $94 as of Q2 2026.
  • Cartesian Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3373 holding.
  • 31 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.